ReviewNeuroscience applied2026
Negative symptoms in schizophrenia: Methodological challenges and emerging solutions for outcome measurement.
Review in Neuroscience applied, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Negative symptoms (NS) affect approximately 60% of individuals with schizophrenia and are associated with poor outcomes. They remain an important unmet therapeutic need, not adequately addressed by available antipsychotic drugs, and they are poorly assessed in most clinical and research settings. In 2005, a consensus conference identified the relevant domains of NS and provided impetus for the development of new outcome measurement instruments. However, after two decades, the new assessment tools still lack regulatory endorsement, and their uptake in clinical practice and research settings is still limited. Two multidisciplinary ECNP workshops (>25 experts) provided qualitative data, which were thematically analyzed, on the limitations of negative symptom assessment and the future perspective of digital phenotyping. Key methodological challenges in assessment are described in the paper, including: a) the heterogeneity of negative symptoms, with at least five distinct domains to be assessed, b) the primary or secondary nature of negative symptoms with respect to other factors, such as extrapyramidal side effects, and severity of psychotic or depressive symptoms; c) the persistence over time of these symptoms. The limitations of legacy scales and new assessment instruments are reviewed, and possible future perspectives related to digital phenotyping are discussed. The experts' suggested steps to improve the assessment of negative symptoms are reported, including the development of patient-centered outcome measures, the validation of digital phenotyping, and the engagement of regulators and other stakeholders in the development or validation of new assessment instruments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.